MAHE signs partnership agreement with KoreAMMR for developing 3D Bioprinted products
Manipal, 17th October 2024: Manipal Centre for Biotherapeutics Research (MCBR), part of Manipal Academy of Higher Education (MAHE), has entered a partnership with Kore Additive Manufacturing and Medical Reconstruction Pvt. Ltd. (KoreAMMR) to co-develop 3D bioprinted therapeutic products.
As part of the collaboration, KoreAMMR has leased a section of MCBR’s Good Manufacturing Practice (GMP) compliant facility to jointly create innovative 3D bioprinted biomedical products with MCBR faculty and researchers.
The partnership facility was officially inaugurated by Dr. Narayan Sabhahit, Pro Vice Chancellor (Technology and Science), MAHE; Dr. P. Giridhar Kini, Registrar, MAHE; Mr. Ravindra Doshi, Managing Director, KoreAMMR; and Mr. Chaitanya Doshi, CEO, KoreAMMR. Both Dr. Giridhar Kini and Mr. Ravindra Doshi praised the collaboration, expressing optimism that the co-developed products would soon reach the commercial market.
Dr. Raviraja N.S., founding Head of MCBR and COO of MAHE, described the agreement as a significant milestone for MCBR, which is celebrating its third anniversary. “This multifaceted partnership will advance the development of 3D bioprinted products for biomedical applications and train skilled professionals in this emerging field,” he said.
KoreAMMR CEO, Mr. Chaitanya Doshi, emphasized the importance of the partnership, noting that manufacturing for clinical trials will begin soon. Dr. Kirthanashri, Coordinator and Associate Professor of MCBR, highlighted that under the agreement, KoreAMMR employees can pursue PhDs at MAHE, and MCBR master’s students will have opportunities to intern at KoreAMMR.
Founded in July 2022, KoreAMMR is incubated at IIT Bombay and RIIDL KJ Somaiya in Mumbai. The company’s mission is to make affordable 3D bioprinted organs for transplantation, drawing inspiration from Dr. Anthony Atala’s successful 3D bioprinted bladder transplant in 2011. KoreAMMR aims to fast-track the clinical trials process through this collaboration with MAHE, with plans to bring their products to market within 5-7 years. They are also working on “organ-on-chip” systems with MCBR, seeking to reduce the need for animal testing in drug development.
Key officials from MAHE, including Dr. Harish Kumar, Director of Corporate Relations; Dr. Arun Maiya, Dean, MCHP; Dr. Srinivas Mutalik, Principal, MCOPS; and Dr. Naveen Salins, Associate Dean, KMC Manipal, attended the signing event.
